SAB Biotherapeutics presents Phase 1 data for SAB-142 in type 1 diabetes at EASD meeting

By Public Technologies
  • SAB Biotherapeutics flagged fresh Phase 1 data for SAB-142 in Stage 3 type 1 diabetes, positioning it as a redosable immunotherapy.
  • Results will be presented in future sessions at the European Association for the Study of Diabetes meeting in Milan on Sep. 28–30, 2026.
  • Disclosed outcomes include early signs of preserving patients’ insulin production, supportive mechanism-of-action evidence, and a safety profile consistent with repeat dosing.
  • Additional readouts cover predictable drug behavior in the body, limited immune reaction risk, and early activity signals in patients with remaining beta-cell function.
  • The program is advancing into the registrational SAFEGUARD study, a key step toward potential approval in the company’s lead indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220830PRIMZONEFULLFEED9829300) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.